EarlySight and PulseSight Therapeutics collaborate to add Cellularis® 2 Retinal Imaging to PST-611 Phase 2 Study
Geneva, Switzerland and Paris, France, 9 October 2026 – EarlySight and PulseSight Therapeutics today announced a collaboration to integrate EarlySight’s Cellularis® 2 retinal imaging device into PulseSight’s soon to start Phase 2a clinical trial of PST-611 in late dry AMD/Geographic Atrophy. The announcement follows PulseSight’s presentation of PST-611 Phase 1 results at the 26th EURETINA Congress in Vienna.
Cellularis® 2 will generate high-resolution longitudinal data to assess the protective effect of PST-611 on retinal tissues as well as the reduction of the GA progression, based on cellular level imaging biomarkers, providing early insights into PST-611 therapeutic activity and complementing the other functional and anatomical endpoints.
Bringing Cellular-Level Endpoints to Drug Development
As an exploratory imaging modality in the PST-611 trial, Cellularis 2 will allow investigators to examine retinal cellular structures and microarchitectural changes that are not visible at the tissue-level resolution of conventional imaging.
“By evaluating retinal changes at the cellular level with Cellularis 2, we have a unique opportunity to observe the impact of PST-611 on protecting retinal pigment epithelium (RPE) and photoreceptors, in ways that have not previously been possible in a clinical trial,” said Judith Greciet, CEO of PulseSight. “This innovative technology will strengthen the assessment of PST-611 early efficacy with novel insights and advance a precise, ground-truth-driven approach to retinal drug development.”
“Sensitive biomarkers may detect biological changes before conventional endpoints become apparent,” added Timothe Laforest, CEO of EarlySight. “We are pleased to explore how Cellularis 2 can support the development of PST-611 and advance precision ophthalmology.”
About EarlySight
EarlySight is a Swiss medical technology company advancing ophthalmic imaging. Its Cellularis® 2 patented device provides non-invasive, cellular-level retinal imaging that helps clinicians and researchers visualize retinal microstructures and investigate imaging biomarkers for clinical research and pharmaceutical development.
For more information, visit www.earlysight.com.
About PulseSight Therapeutics
PulseSight Therapeutics is a clinical-stage biotechnology company developing an innovative vectorized platform to address severe eye diseases with significant unmet medical needs.
Its lead program PST-611, is developed in late dry AMD/Geographic Atrophy; a leading cause of blindness which still represents a large unmet need.
PST-611 is a first-in-class therapy candidate encoding transferrin that plays a key role in the control of iron homeostasis. Dry AMD/GA is associated with a dysregulation of iron levels and oversaturation of transferrin. Through the expression of transferrin, PST-611 intervenes in a key upstream mechanism of GA pathogenesis and, thus, targets the multiple downstream biological cascades that drive the disease progression.
PST-611 has recently completed a first in human Phase 1 study showing its excellent safety profile and positive early signals of efficacy. The company is now initiating a Phase 2a clinical study to confirm PST-611 safety and efficacy profile after repeated administration.
For more information, visit www.pulsesight.com
Media Contacts
EarlySight SA
Timothe Laforest, CEO
info@earlysight.com
www.earlysight.com
PulseSight Therapeutics
Judith Greciet, CEO
contact@pulsesight.com
www.pulsesight.com
